Chlorozotocin was administered as an iv bolus at a dose of 200-225 mg/m2 every 6 weeks for good-risk patients (100 mg/m2 for poor-risk patients) with lung cancer. Only three of 71 fully evaluable patients responded; 12 had stable disease. Myelosuppression was acceptable and no other dose-limiting toxic effects were reported. Chlorozotocin is inactive in non-small cell lung cancer.
|Original language||English (US)|
|Number of pages||3|
|Journal||Cancer Treatment Reports|
|State||Published - 1983|
ASJC Scopus subject areas
- Cancer Research